184 Days Left

Antibacterial Therapeutics Funding Call

Fund Name

PACE Antibacterial Therapeutics Funding Call

Project Length

Up to 2 years

Project Value

Up to £1m



PACE (Pathways to Antimicrobial Clinical Efficacy) aims to provide funding and support for high-value, high-risk, early-phase drug discovery and diagnostic projects.

PACE is looking to help create and advance an exciting and diverse pipeline of preclinical phase projects aimed at treating bacterial infections with high unmet need.

Expressions of interest are invited by 24 November, and an informational webinar will be held on 31 October for interested parties.

Check Your Eligibility

Fund details

Pace’s first funding call will focus solely on early-stage, novel, antibacterial therapeutics.

They are looking for projects directed at the highest-burden drug-resistant bacterial infections and indications, as highlighted by the Lancet study and by the WHO priority list.

In-scope indications are:

  • Lower Respiratory Tract Infections (LRTI)
  • Bloodstream Infections (BSI)
  • Intra-abdominal Infections (IAI)
  • Urinary Tract Infections (UTI)

Projects should be directed at one or more of the following drug-resistant bacteria. They are as follows:

  • Top priority – Novel therapeutics applicable for drug-resistant bacterial infections associated with WHO critical priority Gram-negative pathogens Enterobacteriaceae (prioritising E. coli and K. pneumoniae), A. baumannii, and P. aeruginosa
  • Also eligible – Novel oral therapeutics applicable to drug-resistant S. aureus

Projects should be transformational, to fill a gap for innovative & differentiated antimicrobials in the clinical pipeline. PACE encourages projects that are based on the concept of precision medicine where consideration is given to potential patient stratification and diagnostics requirements.

PACE intends to fund projects looking at:

  • Hit Validation, Hit-to-Lead, Lead Optimisation, Candidate Selection and Early Preclinical phases
  • Any novel targets OR novel chemical classes including but not limited to the following mechanisms; direct-acting and non-direct-acting antimicrobials, anti-virulence approaches, immunomodulatory agents, and potentiators
  • Any modality including but not limited to small molecules, antibodies, peptides, CRISPR-Cas, complex/targeted modalities, phage


Up to 12 applicants will be awarded a maximum of £1 million in grant funding, with projects expected to last up to two years. AMR innovators worldwide are eligible to apply.

Contact us